PROVENTION BIO INC (PRVB) Stock Price, Quote, News and Overview
NASDAQ:PRVB - Nasdaq - US74374N1028 - Common Stock - Currency: USD
PRVB Quote, Performance and Key Statistics
24.98
+0.75 (+3.1%)
The current stock price of PRVB is 24.98 USD. In the past month the price increased by 4.26%. In the past year, price increased by 456.35%.
PRVB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About PRVB
Company Profile
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. The company is headquartered in Red Bank New Jersey, New Jersey and currently employs 174 full-time employees. The company went IPO on 2018-07-24. The firm's product pipeline includes PRV-031 (teplizumab), PRV-3279, PRV-015 (ordesekimab) and PRV-101. Teplizumab is a humanized, anti-CD3 monoclonal antibody (mAb) for the delay of clinical type 1 diabetes (T1D) in at-risk individuals and for patients with newly diagnosed T1D. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins, CD32B and CD79B, for the treatment of systemic lupus erythematosus (SLE) and for the prevention of immunogenicity of biotherapeutics, such as those used in gene therapy. Ordesekimab is a human anti-interleukin 15 (IL-15) mAb for the treatment of gluten-free diet non-responsive celiac disease (NRCD). PRV-101 is a coxsackievirus B (CVB) vaccine to prevent acute CVB infections and, in those patients at-risk, to prevent the CVB-triggered autoimmune damage to pancreatic beta-cells.
Company Info
PROVENTION BIO INC
55 Broad Street, 2Nd Floor
Red Bank New Jersey NEW JERSEY 07701 US
CEO: Ashleigh Palmer
Employees: 174
Company Website: https://www.proventionbio.com/
Phone: 19084289136.0
PROVENTION BIO INC / PRVB FAQ
What is the stock price of PROVENTION BIO INC today?
The current stock price of PRVB is 24.98 USD. The price increased by 3.1% in the last trading session.
What is the ticker symbol for PROVENTION BIO INC stock?
The exchange symbol of PROVENTION BIO INC is PRVB and it is listed on the Nasdaq exchange.
On which exchange is PRVB stock listed?
PRVB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROVENTION BIO INC stock?
12 analysts have analysed PRVB and the average price target is 24.48 USD. This implies a price decrease of -2% is expected in the next year compared to the current price of 24.98. Check the PROVENTION BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROVENTION BIO INC worth?
PROVENTION BIO INC (PRVB) has a market capitalization of 2.37B USD. This makes PRVB a Mid Cap stock.
How many employees does PROVENTION BIO INC have?
PROVENTION BIO INC (PRVB) currently has 174 employees.
What are the support and resistance levels for PROVENTION BIO INC (PRVB) stock?
PROVENTION BIO INC (PRVB) has a support level at 24.41. Check the full technical report for a detailed analysis of PRVB support and resistance levels.
Is PROVENTION BIO INC (PRVB) expected to grow?
The Revenue of PROVENTION BIO INC (PRVB) is expected to grow by 372.61% in the next year. Check the estimates tab for more information on the PRVB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROVENTION BIO INC (PRVB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRVB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRVB, evaluating the profitability, health, valuation and growth aspects
- PROVENTION BIO INC (PRVB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROVENTION BIO INC (PRVB) Sales and EPS estimates to see what analysts future expectations are.
- PROVENTION BIO INC (PRVB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROVENTION BIO INC (PRVB) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROVENTION BIO INC (PRVB) Stock Chart to make your own analysis
- PROVENTION BIO INC (PRVB) Latest news and press-releases to stay up to date.
Does PROVENTION BIO INC (PRVB) stock pay dividends?
PRVB does not pay a dividend.
When does PROVENTION BIO INC (PRVB) report earnings?
PROVENTION BIO INC (PRVB) will report earnings on 2023-08-02, before the market open.
What is the Price/Earnings (PE) ratio of PROVENTION BIO INC (PRVB)?
PROVENTION BIO INC (PRVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.6).
PRVB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PRVB. When comparing the yearly performance of all stocks, PRVB is one of the better performing stocks in the market, outperforming 99.85% of all stocks.
PRVB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRVB. While PRVB seems to be doing ok healthwise, there are quite some concerns on its profitability.
PRVB Financial Highlights
Over the last trailing twelve months PRVB reported a non-GAAP Earnings per Share(EPS) of -1.6. The EPS increased by 12.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.19 |
PRVB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to PRVB. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -18.96% and a revenue growth 372.61% for PRVB